United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read General business news How Kalpataru’s IPO proceeds halved leverage — and what that means for growth Kalpataru Limited’s IPO-driven debt repayment halved its leverage in one quarter, without slowing premium sales growth. Here’s how balance sheet strength is shaping its FY26 trajectory. byPallavi MadhirajuAugust 15, 2025